Although some progress has been made with therapeutic TB vaccines mentioned in this review, such as MV, MIP, DAR‐901, RUTI, M72/AS01E, H56:IC31, and AEC/BC02, challenges remain, including poor sustainability, difficulty in selecting antigen epitopes, and the exclusion of pregnant women from existing TB vaccine trials. The gene discussed is MIP; the disease is tuberculosis.